Sreekanth Dittakavi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5094978/publications.pdf

Version: 2024-02-01

22 papers 131 citations

1683354 5 h-index 10 g-index

24 all docs

24 docs citations

24 times ranked 147 citing authors

#	Article	IF	CITATIONS
1	Validated liquid chromatography–tandem mass spectrometry method for simultaneous quantitation of bendamustine and copanlisib in mouse plasma: Application to a pharmacokinetic study in mice. Biomedical Chromatography, 2022, 36, e5387.	0.8	2
2	DBS Assay with LC-MS/MS for the Determination of Idelalisib, A Selective PI3K-δ Inhibitor in Mice Blood and Its Application to a Pharmacokinetic Study. Drug Research, 2021, 71, 36-42.	0.7	2
3	Validated HPLCâ€MS/MS method for quantitation of AMG 510, a KRAS G12C inhibitor, in mouse plasma and its application to a pharmacokinetic study in mice. Biomedical Chromatography, 2021, 35, e5043.	0.8	11
4	Validated HPLCâ€UV method for simultaneous quantification of phosphatidylinositol 3â€kinase inhibitors, copanlisib, duvelisib and idelalisib, in rat plasma: Application to a pharmacokinetic study in rats. Biomedical Chromatography, 2021, 35, e5015.	0.8	9
5	Bioanalytical method development and validation for establishing bioavailability and bioequivalence. , 2021, , 487-516.		O
6	Validated LC-MS/MS Method for Simultaneous Quantitation of Three PI3K Inhibitors, Copanlisib, Duvelisib and Idelalisib in Mouse Plasma: Application to a Pharmacokinetic Study in Mice. Analytical Chemistry Letters, 2021, 11, 140-152.	0.4	4
7	Uptake and pharmacokinetics of cefuroxime in rabbits after intravitreal, intracameral, and topical dosing: relevance to human ocular injection of cefuroxime. Xenobiotica, 2020, 50, 339-345.	0.5	5
8	Validated LC-MS/MS Method for Simultaneous Quantitation of Enasidenib and its Active Metabolite, AGI-16903 in Small Volume Mice Plasma: Application to a Pharmacokinetic Study. Drug Research, 2020, 70, 41-48.	0.7	0
9	Highâ€throughput screening assay for the quantification of Cer d18:1/16:0, d18:1/24:0, d18:1/24:1, d18:1/18:0, d18:1/14:0, d18:1/20:0, and d18:1/22:0 in HepG2 cells using RapidFire mass spectrometry. Biomedical Chromatography, 2020, 34, e4790.	0.8	3
10	A dried blood spot assay with HPLC–MS/MS for the determination of larotrectinib in mouse blood and its application to a pharmacokinetic study. Biomedical Chromatography, 2020, 34, e4953.	0.8	4
11	Validated HPLC Method for Quantification of a Novel Trk Inhibitor, Larotrectinib in Mice Plasma: Application to a Pharmacokinetic Study. Drug Research, 2020, 70, 101-106.	0.7	2
12	Validated HPLC method for quantification of copanlisib in mice plasma: application to a pharmacokinetic study. ADMET and DMPK, 2020, 8, 113-121.	1.1	4
13	Development and Validation of an HPLC Method for Quantification of Filgotinib, a Novel JAK-1 Inhibitor in Mice Plasma: Application to a Pharmacokinetic Study. Drug Research, 2020, 70, 233-238.	0.7	2
14	A Validated DBS Method for Quantitation of a Novel Mutant IDH1/2 Inhibitor, Vorasidenib Using $10\hat{l}_4$ L Mice Blood: Application to a Pharmacokinetic Study in Mice. Current Pharmaceutical Analysis, 2020, 16, 1140-1147.	0.3	0
15	Validated HPLC method for simultaneous quantification of mutant IDH1/2 inhibitors (enasidenib,) Tj ETQq1 1 0.78 Chromatography, 2019, 33, e4658.	84314 rgB 0.8	BT /Overlock 4
16	High-Affinity Alkynyl Bisubstrate Inhibitors of Nicotinamide <i>N</i> Journal of Medicinal Chemistry, 2019, 62, 9837-9873.	2.9	41
17	Quantitative analysis of enasidenib in dried blood spots of mouse blood using an increasedâ€sensitivity LC–MS/MS method: Application to a pharmacokinetic study. Biomedical Chromatography, 2019, 33, e4491.	0.8	14
18	Quantitation of Ivosidenib, A Novel Mutant IDH1 Inhibitoron Mice DBS: Application to a Pharmacokinetic Study. Drug Research, 2019, 69, 505-511.	0.7	3

#	Article	IF	CITATIONS
19	Validated LC-ESI-MS/MS method for the determination of ivosidenib in 10 µL mice plasma: application to a pharmacokinetic study. ADMET and DMPK, 2019, 7, 131-139.	1.1	2
20	LCâ€ESIâ€MS/MS determination of 4â€methylpyrazole in dog plasma and its application to a pharmacokinetic study in dogs. Biomedical Chromatography, 2018, 32, e4065.	0.8	1
21	LCâ€ESIâ€MS/MS determination of copanlisib, a novel PI3K inhibitor in plasma and its application to a pharmacokinetic study in mice. Biomedical Chromatography, 2018, 33, e4460.	0.8	4
22	LC–MS/MS-ESI method for simultaneous quantification of darolutamide and its active metabolite, ORM-15341 in mice plasma and its application to a pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2017, 145, 454-461.	1.4	12